Who is sponsoring NCT05585814?

NCT05585814 is sponsored by Shanghai Changzheng Hospital.

What drugs are being tested in NCT05585814?

Interventions in NCT05585814: Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab.

What condition does NCT05585814 study?

NCT05585814 studies Locally Advanced Colorectal Cancer.

Is NCT05585814 still recruiting?

NCT05585814 is currently recruiting now. Last updated 14 March 2025.

Last reviewed 2025-03-14 · How we verify

NCT05585814: COBP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Recruiting now Phase 2 Last updated 14 March 2025

What this trial tests

Phase 2 trial testing Capecitabine in Locally Advanced Colorectal Cancer in 30 participants. Currently enrolling.

Timeline

1 May 2023

Primary endpoint
1 October 2024

1 May 2028

Quick facts

Lead sponsor	Shanghai Changzheng Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 May 2023
Primary completion	1 October 2024
Estimated completion	1 May 2028
Sites	1 location across China

Drugs / interventions tested

Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Locally Advanced Colorectal Cancer — all drugs for Locally Advanced Colorectal Cancer →

Sponsor

Shanghai Changzheng Hospital

Who can join

Adults 18 to 75, any sex, with Locally Advanced Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, single-arm study aims to investigate the efficacy and safety of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer patients

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.
Kee JX, Yau JNN, Kumar Muthuramalingam RP, Wang X, et al · · 2025 · cited 6× · PMID 40985211 · DOI 10.1021/acs.chemrev.5c00041
Safety and Efficacy of CAPOX Combined with Bevacizumab plus Pembrolizumab as Neoadjuvant Treatment of pMMR/MSS Type Locally Advanced Colorectal Cancer Patients: Study Protocol for a Single-arm, Phase Ib, Prospective Trial (COBP)
Wang A, Zhang P, Yu D, Zhu H, et al · · 2023 · DOI 10.21203/rs.3.rs-3334504/v1

Verify or expand the search:

Other trials of Capecitabine

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer · Phase 3 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Locally Advanced Colorectal Cancer

Currently open trials in the same condition.

NCT06846268 — Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer · Phase 2 · recruiting
NCT06550453 — Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutate · Phase 4 · recruiting
NCT04301557 — PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer · Phase 2 · active not recruiting

Other Shanghai Changzheng Hospital trials

Trials by the same sponsor.

NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
Last refreshed: 14 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing